•ContraFect Corporation is dedicated to developing technologies, treatments, and products that will target and kill the most virulent and resistant microorganisms.
•ContraFect’s current therapy focuses on monotherapy, or the use of one drug at a time, which exerts an evolutionary pressure on mutant strains and promotes the formation of drug-resistant pathogens.
•Located within iPark on Hudson
•Investment: $15 million
•Address: 28 Wells Avenue, Bldg #3, 3rd Floor